Taro Pharma to buy Alchemee formerly The Proactiv Company, from Galderma

23 Feb 2022 , 12:48 PM

Sun Pharma announced that Galderma and Taro Pharmaceutical Industries have signed a definitive agreement for Taro to acquire Alchemee, formerly The Proactiv Company (TPC), from Galderma. The agreement between Galderma and Taro includes Alchemee’s business and assets around the world, including the Proactiv brand.

Uday Baldoota, CEO at Taro said, “We are excited to add Proactiv to Taro’s broad portfolio of prescription and over-thecounter dermatology products. We look forward to welcoming the Alchemee team into Taro and working together to continue to make a difference to the millions of people living with acne around the world.”

Proactiv has been used and trusted by millions around the world for more than 25 years. Originally set up as a subscription-based business, Proactiv quickly became a leading U.S. consumer acne brand.

Flemming Ørnskov, M.D., MPH, CEO at Galderma said, “we are proud of the work we have done together to serve customers suffering from acne
around the world through Proactiv. I am confident that Taro is the right owner to build on Alchemee’s strong foundation. Their vision is aligned to Alchemee which comes with an incredible legacy and brand equity, and a great team with a clear plan for future success.”

The acquisition is subject to customary closing conditions and any necessary regulatory approvals. Financial terms of the transaction have not been disclosed.

At around 12.42 pm, Sun Pharma was trading at Rs844.55 per piece marginally down on BSE.